Cargando…

Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy

Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy. Despite this benefit, gluco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quattrocelli, Mattia, Zelikovich, Aaron S., Salamone, Isabella M., Fischer, Julie A., McNally, Elizabeth M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902991/ https://www.ncbi.nlm.nih.gov/pubmed/33104035 http://dx.doi.org/10.3233/JND-200556

Ejemplares similares

Moderate exercise improves function and increases adiponectin in the mdx mouse model of muscular dystrophy
por: Zelikovich, Aaron S., et al.
Publicado: (2019)

Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms
por: Salamone, Isabella M., et al.
Publicado: (2022)

An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy
por: Zelikovich, Aaron S., et al.
Publicado: (2022)

Mechanisms of muscle weakness in muscular dystrophy
por: Goldstein, Jeffery A., et al.
Publicado: (2010)

Genetic modifiers of muscular dystrophy act on sarcolemmal resealing and recovery from injury
por: Quattrocelli, Mattia, et al.
Publicado: (2017)

A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping
por: Demonbreun, Alexis R., et al.
Publicado: (2019)

Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy
por: Demonbreun, Alexis R., et al.
Publicado: (2021)

The superhealing MRL background improves muscular dystrophy
por: Heydemann, Ahlke, et al.
Publicado: (2012)

Muscle mitochondrial remodeling by intermittent glucocorticoid drugs requires an intact circadian clock and muscle PGC1α
por: Quattrocelli, Mattia, et al.
Publicado: (2022)

Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel
por: Spurney, Christopher F, et al.
Publicado: (2021)

Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents
por: Herbelet, Sandrine, et al.
Publicado: (2020)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy
por: Murakami, Terumi, et al.
Publicado: (2021)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
por: Zhang, Tianyuan, et al.
Publicado: (2021)

Satellite Cells: Regenerative Mechanisms and Applicability in Muscular Dystrophy
por: de Souza, Gustavo Torres, et al.
Publicado: (2015)

Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
por: ANGELINI, CORRADO, et al.
Publicado: (2012)

Lung function monitoring in patients with duchenne muscular dystrophy on steroid therapy
por: Machado, Darlene L, et al.
Publicado: (2012)

Author Correction: Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy
por: Murakami, Terumi, et al.
Publicado: (2022)

miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy
por: Sanson, M., et al.
Publicado: (2020)

An actin-dependent annexin complex mediates plasma membrane repair in muscle
por: Demonbreun, Alexis R., et al.
Publicado: (2016)

Muscular Dystrophy: Disease Mechanisms and Therapies
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

Positive effect of the combination of multilevel contracture release and glucocorticoid treatment in Duchenne muscular dystrophy
por: Weiß, Claudia, et al.
Publicado: (2020)

Growth Hormone Therapy for Children With Duchenne Muscular Dystrophy and Glucocorticoid Induced Short Stature
por: Lavi, Eran, et al.
Publicado: (2021)

Cellular and molecular mechanisms underlying muscular dystrophy
por: Rahimov, Fedik, et al.
Publicado: (2013)

The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression
por: Kinnett, Kathi, et al.
Publicado: (2017)

Description of a Novel Mechanism Possibly Explaining the Antiproliferative Properties of Glucocorticoids in Duchenne Muscular Dystrophy Fibroblasts Based on Glucocorticoid Receptor GR and NFAT5
por: Herbelet, Sandrine, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
por: Howard, Zachary M., et al.
Publicado: (2022)

Presence of mechanical dyssynchrony in duchenne muscular dystrophy
por: Hor, Kan N, et al.
Publicado: (2011)

Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ
por: Lamar, Kay-Marie, et al.
Publicado: (2016)

The super-healing MRL strain promotes muscle growth in muscular dystrophy through a regenerative extracellular matrix
por: O’Brien, Joseph G., et al.
Publicado: (2023)

Intermittent prednisone treatment in mice promotes exercise tolerance in obesity through adiponectin
por: Quattrocelli, Mattia, et al.
Publicado: (2022)

A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKIIβ Signaling in Limb Girdle Muscular Dystrophy
por: Liu, Jian, et al.
Publicado: (2020)

Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status
por: McDonald, Craig M, et al.
Publicado: (2023)

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
por: Bez Batti Angulski, Addeli, et al.
Publicado: (2023)

The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy
por: Annexstad, E. J., et al.
Publicado: (2019)

Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy
por: Zhang, Shu, et al.
Publicado: (2021)

Efficacy and safety of glucocorticoids in the treatment of progressive muscular dystrophy in children: a systematic review and meta-analysis
por: Ru, Liang, et al.
Publicado: (2021)

Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
por: Kang, Peter B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0kbp9hbe4t27u6hbict4u70rmf